Pretreatment levels of bone turnover and the antifracture efficacy of alendronate: The fracture intervention trial
Pretreatment levels of bone turnover and the antifracture efficacy of alendronate: The fracture intervention trial
复制标题
DOI：
10.1359/jbmr.051018
复制
发表时间：
2006-02-01
影响因子：
6.2
通讯作者：
Black, DM
中科院分区：
文献类型：
--
作者：
Bauer, DC;Garnero, P;Black, DM
简介：之前的试验表明，在接受双膦酸盐治疗的女性中，高骨转换与 BMD 的更大增加相关。治疗前骨转换水平对抗骨折疗效的影响尚未得到充分研究。材料和方法：我们将股骨颈 BMD T 评分为 56.8 ng/ml 的 55-80 岁女性随机分组。基线时没有骨质疏松症的女性的结果相似。尽管未达到统计学显着性，但在 BSALP 基线水平上观察到了类似的趋势。相反，骨质疏松女性的脊柱骨折治疗效果根据治疗前标志物水平没有显着差异。非骨质疏松女性的脊柱骨折治疗效果与基线 BSALP 相关（趋势 P = 0.05）。总之，阿仑膦酸钠对非脊柱骨折的疗效在高预处理、PINP 的骨质疏松症和非骨质疏松症女性中均较高。如果在其他研究中得到证实，这些发现表明双磷酸盐治疗可能对骨转换升高的女性最有效。
Introduction: Previous trials have shown that high bone turnover is associated with greater increases in BMD among bisphosphonate-treated women. The influence of pretreatment bone turnover levels on antifracture efficacy has not been well studied.Materials and Methods: We randomized women 55-80 years of age with femoral neck BMD T scores 56.8 ng/ml). Results were similar among women without osteoporosis at baseline. Although they did not reach statistical significance, similar trends were observed with baseline levels of BSALP. Conversely, spine fracture treatment efficacy among osteoporotic women did not differ significantly according to pretreatment marker levels. Spine fracture treatment efficacy among nonosteoporotic women was related to baseline BSALP (P = 0.05 for trend). In summary, alendronate nonspine fracture efficacy is greater among both osteoporotic and nonosteoporotic women with high pretreatment,,PINP. If confirmed in other studies, these findings suggest that bisphosphonate treatment may be most effective in women with elevated bone turnover.